Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

cefpodoxime (Rx)Brand and Other Names:Vantin

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

oral suspension

  • 50mg/5mL
  • 100mg/5mL

tablet

  • 100mg
  • 200mg
more...

Acute Bronchitis & Acute Exacerbations of Chronic Bronchitis

200 mg PO q12hr for 10 days

Acute Community-Acquired Pneumonia

200 mg PO q12hr for 14 days

Acute Maxillary Sinusitis

200 mg PO q12hr for 10 days

Pharyngitis/Tonsillitis

100 mg PO q12hr for 5-10 days

Skin/Skin Structure Infections

400 mg PO q12hr for 7-14 days

Gonorrhea

Uncomplicated gonorrhea in men and women; rectal gonococcal infections in women

200 mg PO once

Uncomplicated Urinary Tract Infections

100 mg PO q12hr for 7-14 days

Dosing Modifications

Renal impairment

  • CrCl <30 mL/min: Give q24hr
  • Hemodialysis: Give 3 times weekly after dialysis

Hepatic impairment

  • Dosage adjustment not necessary

Dosing Considerations

Susceptible organisms

  • Bacteroides fragilis, Clostridium perfringens, Escherichia coli, Haemophilus influenzae, Klebsiella spp, Moraxella catarrhalis, Neisseria gonorrhoeae, Proteus mirabilis, staphylococci, group A beta-hemolytic streptococci, Streptococcus pyogenes

Dosage Forms & Strengths

oral suspension

  • 50mg/5mL
  • 100mg/5mL

tablet

  • 100mg
  • 200mg
more...

Acute Maxillary Sinusitis

<2 months: Safety and efficacy not established

2 months-12 years: 5 mg/kg PO q12hr for 10 days; individual doses not to exceed 200 mg 

>12 years: 200 mg PO q12hr for 10 days

Acute Otitis Media

<2 months: Safety and efficacy not established

2 months-12 years: 5 mg/kg PO q12hr for 5 days; individual doses not to exceed 200 mg 

>12 years: 200 mg PO q12hr for 5 days

Pharyngitis/Tonsillitis

<2 months: Safety and efficacy not established

2 months-12 years: 5 mg/kg PO q12hr for 5-10 days; individual doses not to exceed 100 mg 

>12 years: 100 mg PO q12hr for 5-10 days

Next

Interactions

Interaction Checker

cefpodoxime and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            >10%

            Diarrhea in infants and toddlers (15.4%)

            Diaper rash (12.1%)

            1-10%

            Diarrhea (7.4%)

            Nausea (3.8%)

            Vaginal infection (3.1%)

            Vomiting (1.1-2.1%)

            Abdominal pain (1.6%)

            Rash (1.4%)

            Headache (1.1%)

            Previous
            Next

            Warnings

            Contraindications

            Documented hypersensitivity

            Cautions

            Reduce dosage by 50% if CrCl is 10-30 mL/min and by 75% if CrCl is <10 mL/min (high dosages may cause CNS toxicity)

            Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy

            Use with caution in patients with history of penicillin allergy

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy category: B

            Lactation: Drug excreted in breast milk in low concentrations; not recommended

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Mechanism of Action

            Bactericidal against gram-positive and gram-negative bacteria; inhibits bacterial cell-wall synthesis by binding to 1 or more of penicillin-binding proteins; bacteria eventually lyse because activity of cell-wall autolytic enzymes continues while cell-wall assembly is arrested

            Absorption

            Bioavailability: 50%; acid stable

            Peak plasma time: ≤1 hr

            Distribution

            Distributed well into tissues, including lungs and tonsils; penetrates into pleural fluid

            Protein bound: 18-23%

            Metabolism

            Metabolized in liver to active metabolite

            Elimination

            Half-life: 2-3 hr; prolonged with renal impairment

            Excretion: Urine (80% as unchanged drug) in 24 hr

            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.